60 Degrees Pharmaceuticals Future Growth
Future criteria checks 2/6
60 Degrees Pharmaceuticals's earnings are forecast to decline at 1.1% per annum while its annual revenue is expected to grow at 84.4% per year. EPS is expected to grow by 87.2% per annum.
Key information
-1.1%
Earnings growth rate
87.2%
EPS growth rate
| Pharmaceuticals earnings growth | 23.9% |
| Revenue growth rate | 84.4% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 23 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 4 | -9 | N/A | -13 | 1 |
| 12/31/2025 | 2 | -8 | N/A | -9 | 2 |
| 12/31/2024 | 1 | -8 | N/A | -6 | 2 |
| 9/30/2024 | 0 | -8 | -4 | -4 | N/A |
| 6/30/2024 | 0 | -2 | -6 | -6 | N/A |
| 3/31/2024 | 0 | -1 | -5 | -5 | N/A |
| 12/31/2023 | 0 | -4 | -5 | -5 | N/A |
| 9/30/2023 | 0 | -4 | -5 | -5 | N/A |
| 6/30/2023 | 0 | -9 | -1 | -1 | N/A |
| 3/31/2023 | 0 | -8 | -1 | -1 | N/A |
| 12/31/2022 | 1 | -6 | -1 | -1 | N/A |
| 9/30/2022 | 1 | -6 | -1 | -1 | N/A |
| 12/31/2021 | 6 | -4 | -1 | -1 | N/A |
| 12/31/2020 | 3 | -3 | 0 | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SXTP is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SXTP is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SXTP is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SXTP's revenue (84.4% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: SXTP's revenue (84.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SXTP's Return on Equity is forecast to be high in 3 years time